AGENDA

Welcome & Introductions
8:00 - 8:15 am CT

Chris Prakash, MD 
Director, Quality Services - Texas Oncology
Chair, Med Onc Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris


Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes
8:15 - 9:15 am CT | 1.0 CME/CE

Robert Coleman, MD
Chief Medical Officer
Sarah Cannon Research Institute
Gynecologic Oncologist
The US Oncology Network

Chris Prakash, MD 
Director, Quality Services - Texas Oncology
Chair, Med Onc Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris


Navigating New Evidence in the Treatment of HER2-Expressing Metastatic Breast Cancer in Rural and Underserved Communities
9:15 - 10:15 am CT | 1.0 CME/CE

Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Med Onc Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris


Break
10:15 - 10:30 am CT


Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care
10:30 - 11:30 am CT | 1.0 CME/CE

Martin H. Voss, MD
Clinical Director, Genitourinary Oncology Service
Associate Member
Memorial Sloan Kettering Cancer Center

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Med Onc Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris


Integrating the Latest Evidence in Melanoma Care to Address Health Equity
11:30 am - 12:30 pm CT | 1.0 CME/CE

Michael A. Davies, MD, PhD
Professor and Chair, Department of Melanoma Medical Oncology
University of Texas MD Anderson Cancer Center

Chris Prakash, MD 
Director, Quality Services - Texas Oncology
Chair, Med Onc Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris


Break
12:30 - 12:45 pm CT


Integrating the Latest Evidence on Management of Basal Cell Carcinoma: Improving Outcomes in Rural and Underserved Communities
12:45 - 1:45 pm CT | 1.0 CME/CE

David Miller, MD, PhD
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Hospital

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Med Onc Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris


Integrating Novel Treatment Approaches for Cutaneous Squamous Cell Carcinoma: Strategies for Improving Equitable and Timely Access to Care
1:45 - 2:45 pm CT | 1.0 CME/CE

David Miller, MD, PhD
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Hospital

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Med Onc Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris

Agenda as of 3/23/23. Session order subject to change.